Emergency Contraception

Filter Standards and Guidance documents

FSRH Clinical Guideline: Emergency Contraception (March 2017, amended December 2020)

03 December 2020

This document updates previous Faculty of Sexual & Reproductive Healthcare (FSRH) guidance and aims to summarise the available evidence on emergency contraception (EC). The guidance is intended for use by health professionals providing EC. This document was updated in December 2020.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH CEU Statement Response to Edelman 2022 (August 2022)

04 August 2022

A new study (Edelman 2022) adds to the evidence around use of LNG-EC by those with higher weight/BMI but does not give a clear enough picture to inform any change in guidance.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

Please read this guidance document in conjunction with any relevant clinical statements for this topic.

FSRH CEU Statement: Response to Endler 2022 (July 2022)

06 July 2022

A recently-published literature review considers the evidence around mechanism of action of levonorgestrel oral emergency contraception (LNG-EC). The findings support current FSRH guidance on emergency contraception, and are reassuring for those with ethical concerns about post-ovulation effects.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH CEU response to European Medicines Agency recommendations regarding use of ulipristal acetate for management of uterine fibroids (February 2018)

01 February 2018

The European Medicines Agency (EMA) is currently reviewing the safety of use of Esmya® (ulipristal acetate) for management of uterine fibroids. This review follows reports of a very small number of cases worldwide of serious liver injury in women using Esmya. Until the review process is complete, temporary restrictions have been placed on commencing treatment with Esmya and guidelines for monitoring liver function in women already taking Esmya have been introduced. The EMA recommendations are available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/02/news_detail_002902.jsp&mid=WC0b01ac058004d5c1

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date